DAORX operates as a Wyoming DAO LLC under SF0038. All rights administration, data licensing, and distribution activities are governed by the following disclosures.

Wyoming DAO LLC — SF0038 Disclosure

DAORX is organized as a Wyoming DAO LLC pursuant to Wyoming Statutes §§ 17-31-101 through 17-31-116 (SF0038, Chapter 2021). The DAO LLC structure provides limited liability to members while permitting governance and operational logic to be encoded in smart contracts on Hyperledger Fabric. Wyoming law expressly recognizes DAO LLC smart contracts as legally binding and enforceable under Wyoming law. Member interests are non-transferable administrative tokens; they do not represent equity, profit interests, or investment contracts.

Development-Stage Notice

DAORX is a development-stage platform. No licensed cohort data transactions have occurred. No rights administration distributions have been made. All marketplace cohort listings, dashboard statistics, and ledger data shown on this platform are illustrative only. Platform infrastructure (Hyperledger Fabric, FHIR API, SMART on FHIR authorization) is deployed and operational; the rights administration layer (split rule registry, distribution routing, licensing marketplace) is in active development. Figures described as illustrative are not projections, forecasts, or guarantees of future performance.

Securities Law Notice — Howey Analysis

DAORX administrative tokens and rights instruments are not securities under the SEC Howey test (SEC v. W.J. Howey Co., 328 U.S. 293 (1946)). There is no investment of money in a common enterprise with expectation of profits solely from the efforts of others. Rights instruments represent a patient’s own data access authorization — a contractual right, not an investment contract. Administration distributions are not profits; they are fee-for-service licensing proceeds routed per a registered consent instrument. No token sale, no offering, no underwriting. MRT-POLICY prohibits earn/stake/yield/DeFi/invest language platform-wide.

HIPAA & Data Licensing Notice

All cohort data licensed through the DAORX marketplace is de-identified pursuant to HIPAA Safe Harbor (45 CFR §164.514(b)) prior to any licensed access. No individually identifiable health information (IIHI) is transferred in any licensing transaction. MyRxWallet North America Corporation is a HIPAA-covered entity. The FHIR R4 API complies with ONC 45 CFR Part 170 and passed the ONC Inferno v8.0.0 test suite on April 17, 2026 (317/317 sub-tests). CHPL certification listing is in process — ONC (g)(10) official certification is pending CHPL registration. Patient consent is verified on-chain via the consent chaincode before any data query is authorized.

MRT-POLICY Summary

DAORX is governed by the MyRx Rights Token Policy (MRT-POLICY). Section 4 prohibits earn, stake, yield, DeFi, redeem, and invest language in all platform communications. “Royalty” means a fee for licensed use of an intellectual property right — in this context, the right to query a patient’s FHIR records. “Administration” refers to the routing of licensing proceeds per the registered rights instrument. “Distribution” refers to the allocation of administration proceeds per split rules. These terms describe a contractual fee-for-service arrangement, not investment returns. All platform language is reviewed for compliance with MRT-POLICY prior to publication.

Compliance Inquiries

For regulatory, legal, or compliance questions regarding DAORX rights administration.